Endo International (NASDAQ:ENDP) (TSE:ENL) updated its FY19 earnings guidance on Monday. The company provided earnings per share guidance of $2.00-2.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.17. The company issued revenue guidance of $2.76-2.96 billion, compared to the consensus revenue estimate of $2.86 billion.
Several research firms recently issued reports on ENDP. Royal Bank of Canada lowered shares of Endo International from an outperform rating to a sector perform rating and dropped their price target for the stock from $11.00 to $6.00 in a research report on Thursday, July 11th. BidaskClub lowered shares of Endo International from a sell rating to a strong sell rating in a report on Thursday, July 18th. Morgan Stanley lowered shares of Endo International from an equal weight rating to an underweight rating and dropped their price objective for the stock from $8.00 to $3.00 in a report on Monday, July 15th. Citigroup lowered shares of Endo International from a buy rating to a neutral rating and dropped their price objective for the stock from $19.00 to $5.00 in a report on Monday, June 17th. Finally, Zacks Investment Research lowered shares of Endo International from a buy rating to a hold rating in a report on Wednesday, May 15th. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the stock. Endo International has a consensus rating of Hold and a consensus price target of $10.55.
ENDP stock traded up $0.07 during midday trading on Wednesday, reaching $2.32. The company’s stock had a trading volume of 133,030 shares, compared to its average volume of 5,315,445. The stock’s 50-day moving average price is $3.69. The stock has a market capitalization of $533.79 million, a PE ratio of 0.80 and a beta of 1.14. Endo International has a 52 week low of $2.21 and a 52 week high of $18.50.
In other news, Director Roger H. Kimmel sold 34,951 shares of Endo International stock in a transaction on Monday, June 17th. The shares were sold at an average price of $3.93, for a total transaction of $137,357.43. Following the transaction, the director now directly owns 148,309 shares of the company’s stock, valued at $582,854.37. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 1.50% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.